Terms ending in 2038
Every in-force patent on Acceleron Pharma Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,021,527 | Transforming Growth Factor Beta Receptor Type II Fusion Polypeptides In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 12,195,519 | Transforming Growth Factor-Beta (TGF-BETA) Receptor Type II Fusion Polypeptides In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 11,267,865 | Variant Actriib Proteins and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 12,240,887 | Variant Actriib Proteins and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 12,421,295 | Tgf-Beta Superfamily Type I and Type II Receptor Heteromultimers and Uses Thereof In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | |
| US 12,673,998 | ALK7 Binding Proteins and Uses Thereof In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | |
| US 12,194,076 | Methods and Compositions for Treating Myelofibrosis In force · Medium confidence | Suragani, Rajasekhar Naga Venkata Sai | In force | Medium confidence | |
| US 12,054,753 | Methods of Treatment of Muscular Dystrophy with ALK4:ACTRIIB Heteromultimers In force · High confidence | Acceleron Pharma Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.